Harmalol (hydrochloride hydrate)

DESCRIPTION

A β-carboline alkaloid and an active metabolite of harmaline; an inhibitor of DYRK1A (IC50 = 0.63 µM); an inhibitor of MAO-A (IC50 = 0.66 µM); selective for DYRK1A over Cdk1, Cdk5, CK1α1, Clk4, DYRK2, Pim-1, and GSK3β but also inhibits DYRK1B and Clk1 at 10 µM; inhibits proliferation of H4 human glioblastoma cells (IC50s = 23.7 µM); reduces TCDD-induced increases in CYP1A1 levels in HepG2 cells and prevents TCDD-induced activation of AhR in guinea pig hepatic cytosolic extracts; reduces glutamate-induced cytotoxicity, cytochrome c release, caspase-3 activation, and ROS production in PC12 cells at 25 µM

DETAILS

Inchi: InChI=1S/C12H12N2O.ClH.2H2O/c1-7-12-10(4-5-13-7)9-3-2-8(15)6-11(9)14-12;;;/h2-3,6,14-15H,4-5H2,1H3;1H;2*1H2
Purity: ≥98%
Raptas: Product Type|Biochemicals|Antioxidants||Product Type|Biochemicals|Kinase Inhibitors|Dual Specificity Kinases||Product Type|Biochemicals|Natural Products|Alkaloids||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Product Type|Biochemicals|Xenobiotic Metabolites||Research Area|Cancer||Research Area|Cell Biology|Cell Death|Apoptosis||Research Area|Neuroscience|Neuroprotection||Research Area|Oxidative Stress & Reactive Species|Antioxidant Activity||Research Area|Oxidative Stress & Reactive Species|Reactive Oxygen||Research Area|Toxicology & Xenobiotic Metabolism|Cell Health & Viability||Research Area|Toxicology & Xenobiotic Metabolism|Cytochrome P450s|CYP1A1||Research Area|Toxicology & Xenobiotic Metabolism|Drug Metabolites||Research Area|Toxicology & Xenobiotic Metabolism|Xenobiotic Sensing
Smiles: OC1=CC=C2C(NC3=C2CCN=C3C)=C1.Cl.O.O
Inchikey: OYKGNQNESCZSHQ-UHFFFAOYSA-N
Cas Number: 6028-00-8
Formulation: A solid
Item Origin: Plant/Unspecified sp.
Storage Temp: -20
Shipping Temp: -20
Formula Markup: C12H12N2O • HCl [2H2O]
Formula Weight: 272.7
Shelf Life Days: 1460